title: XL888 Limits Vemurafenib-Induced Proliferative Skin Events by Suppressing Paradoxical MAPK Activation.
authors.affiliation: Department of Tumor Biology, The Moffitt Cancer Center, Tampa, Florida, USA.
authors.forename: Manali
authors.initials: M
authors.lastname: Phadke
authors.affiliation: Department of Cutaneous Oncology, The Moffitt Cancer Center, Tampa, Florida, USA.
authors.forename: Geoffrey T
authors.initials: GT
authors.lastname: Gibney
authors.affiliation: Department of Cutaneous Oncology, The Moffitt Cancer Center, Tampa, Florida, USA.
authors.forename: Carolyn J
authors.initials: CJ
authors.lastname: Rich
authors.affiliation: Department of Tumor Biology, The Moffitt Cancer Center, Tampa, Florida, USA.
authors.forename: Inna V
authors.initials: IV
authors.lastname: Fedorenko
authors.affiliation: Department of Biostatistics, The Moffitt Cancer Center, Tampa, Florida, USA.
authors.forename: Y Ann
authors.initials: YA
authors.lastname: Chen
authors.affiliation: Department of Cutaneous Oncology, The Moffitt Cancer Center, Tampa, Florida, USA.
authors.forename: Ragini R
authors.initials: RR
authors.lastname: Kudchadkar
authors.affiliation: Department of Cutaneous Oncology, The Moffitt Cancer Center, Tampa, Florida, USA.
authors.forename: Vernon K
authors.initials: VK
authors.lastname: Sondak
authors.affiliation: Department of Cutaneous Oncology, The Moffitt Cancer Center, Tampa, Florida, USA.
authors.forename: Jeffrey
authors.initials: J
authors.lastname: Weber
authors.affiliation: Department of Cutaneous Oncology, The Moffitt Cancer Center, Tampa, Florida, USA. Electronic address: jane.messina@moffitt.org.
authors.forename: Jane L
authors.initials: JL
authors.lastname: Messina
authors.affiliation: Department of Tumor Biology, The Moffitt Cancer Center, Tampa, Florida, USA; Department of Cutaneous Oncology, The Moffitt Cancer Center, Tampa, Florida, USA. Electronic address: keiran.smalley@moffitt.org.
authors.forename: Keiran S M
authors.initials: KSM
authors.lastname: Smalley
mesh_terms: D053961:Azabicyclo Compounds / Q000494:pharmacology*; D001707:Biopsy, Needle; D049109:Cell Proliferation / Q000187:drug effects; D004347:Drug Interactions; D006801:Humans; D007150:Immunohistochemistry; D007211:Indoles / Q000494:pharmacology*; D008545:Melanoma / Q000188:drug therapy / Q000235:genetics / Q000473:pathology; D020929:Mitogen-Activated Protein Kinase Kinases / Q000187:drug effects / Q000378:metabolism*; D010795:Phthalic Acids / Q000494:pharmacology*; D012680:Sensitivity and Specificity; D012867:Skin / Q000187:drug effects* / Q000473:pathology; D012878:Skin Neoplasms / Q000188:drug therapy / Q000235:genetics / Q000473:pathology; D013449:Sulfonamides / Q000494:pharmacology*; D046509:Tissue Culture Techniques; D000077484:Vemurafenib
chemical_list: D053961:Azabicyclo Compounds; D007211:Indoles; D010795:Phthalic Acids; D013449:Sulfonamides; C559121:XL 888; D000077484:Vemurafenib; D020929:Mitogen-Activated Protein Kinase Kinases